40 Years of Small Molecule Pharmaceutical Contract Manufacturing and Introducing the New Cambrex Brand
The manufacturing of active pharmaceutical ingredients (APIs and intermediates) is a complex, specialised activity, requiring the expert intertwining of chemistry and engineering. Historically, this was performed by large pharmaceutical companies, who saw value in taking the drug seamlessly from drug discovery to large-scale manufacture and keeping the whole process under one roof. In parallel to this, contract manufacturing organisations (CMOs) arose to support production when additional capacity was needed or specialised chemistry required.
This webinar aims to present an expert review of the last 40 years of the CMO industry for small molecules. In addition to in-depth analysis by Cambrex, performed over the period 1975-2015, a series of primary research interviews with industry experts was undertaken. In total, the views of 10 industry veterans, each of whom had no less than 25 years’ experience in the CMO industry, have been presented.
This webinar aims to present the audience with an historic overview of how contract manufacturing has evolved since the early days of being a niche, opportunistic industry, with just a few suppliers where most manufacturing was still routinely performed in-house within large pharmaceutical plants, to one that blossomed into a $50-60bn enterprise, where outsourced pharmaceutical manufacturing has now become the rule rather than the exception.
After looking back over the last 40 years, Cambrex will then offer a forward-looking opinion on what to expect for the CMO industry in the coming 5 years from 2016 through to 2020. The webinar will then culminate in an unveiling of the new Cambrex brand – with a focus on Active Ingredients | Dynamic People – and how the organization is well positioned to become the leading CMO in small molecule manufacturing by 2020.
Presented by
Dr. Matthew Moorcroft,
VP of Global Marketing / Cambrex
Matt is the Vice President of Global Marketing and Communications for Cambrex. Prior to joining Cambrex, he worked for Lonza and held a number of roles including Head of Global Marketing, VP Generics and Biosimilars, and Head of Strategy, Pharmaceuticals and Biologics.
After gaining experience in the custom development & manufacturing business, he developed models for biosimilars and generic drug products. He has 15 years of commercial and scientific experience in the pharmaceutical, biotechnology and chemical industry covering both innovative and generic medicines. Matt graduated with a Ph.D. in chemistry from the University of Oxford.
Alex Maw,
Director, Marketing and Communications
Alex is the Director of Marketing and Communications for Cambrex with responsibility for corporate marketing and brand strategy. Prior to joining Cambrex, she held group marketing and communications responsibilities for Consort Medical plc and its divisions: Aesica and Bespak and held a range of marketing roles at Aesica prior to the acquisition of the company by Consort Medical. She has specific experience in driving brand strategy and growth in the pharmaceutical contract services sector.
Alex graduated with a BA (Hons) in Marketing Management from Newcastle Business School, Northumbria University and has a Professional Postgraduate Diploma in Marketing from the Chartered Institute of Marketing. Alex also holds Chartered Marketer status.
